• Takeda ditches late-stage Ninlaro trial pharmatimes
    June 11, 2019
    Takeda has announced the premature ending of its Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis, due to the study not meeting the first of two primary endpoints.
PharmaSources Customer Service